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Abstract: Population-based screening studies have shown celiac disease to be one of the most common
chronic gastrointestinal diseases. Nevertheless, because of the diverse clinical presentation, the great
majority of patients remain unrecognized. Particularly difficult to identify are the multifaceted
extraintestinal symptoms that may appear at variable ages. Although the pathogenesis and
long-term outcome of these manifestations are still poorly established, there is some evidence that
unrecognized celiac disease predisposes to severe complications if not diagnosed and prevented with
an early-initiated gluten-free diet. Therefore, it is of utmost importance that physicians of different
disciplines learn to recognize celiac disease in individuals with non-gastrointestinal symptoms. In the
future, more studies are needed to clarify the factors affecting development and prognosis of the
extraintestinal manifestations.
Keywords: celiac disease; extraintestinal; recognition; diagnosis; clinical presentation; gluten-free
diet; prognosis
1. Introduction
During the past few decades, we have come to recognize that celiac disease is among the most
common gastrointestinal diseases, both in children and adults. The true prevalence of the disease in
many Western countries is estimated to be as high as 1–3% and is increasing [1]. At the same time,
modern sensitive and specific transglutaminase 2 (TG2) antibody based serological tests have made
non-invasive case finding and screening of celiac disease considerably easier. In theory, the simplified
diagnostics should have also increased the proportion of clinically detected cases, and this has indeed
been the case in some, particularly Northern European, countries [2,3]. However, even in these areas,
let alone globally, celiac disease remains seriously underdiagnosed. For example, it is estimated that
in the United States, more than 90% of all affected patients are unrecognized [4]. It must also be
emphasized that, instead of clinical case finding, a substantial proportion of patients in the aforesaid
countries are found by at-risk group screening [5].
The evident difficulty in identifying celiac disease may be explained by in part by the
heterogeneous and often vague clinical presentations. While the characteristic malabsorptive disease
and gastrointestinal symptoms are relatively well known, the majority of celiac disease patients
may in fact suffer from extraintestinal manifestations. These may affect almost every organ of the
body, including the nervous system, liver, skin, and reproductive and musculoskeletal system [6–9].
Furthermore, some of these manifestations appear in early childhood, while the rest are not seen
until adulthood, including in the elderly. Although evidence is limited, some extraintestinal
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presentations may lead to permanent complications if not recognized and treated early enough.
Therefore, extraintestinal celiac disease needs to be recognized by physicians of various specialities,
including gastroenterologists, internists, pediatricians, neurologists, dermatologists, gynecologists,
and particularly general practitioners and family doctors.
In this review, we will provide an overview about current understanding of the pathogenesis
and age-related clinical outcomes of the variable extraintestinal manifestations of celiac disease.
In particular, we aim to improve the early recognition and diagnostic yield of this multifaceted
condition, and subsequently reduce the risk of ill health and long-term complications.
2. Changes in Clinical Presentation
Celiac disease was long considered as a rare malabsorptive disease affecting mainly infants and
toddlers. Classical symptoms included failure to thrive, chronic diarrhea, and abdominal distention.
In the 1970s, the incidence of ‘typical’ celiac disease patients seemed to decrease and concurrently,
older patients with milder symptoms were identified. When screening for celiac disease with sensitive
and specific endomysium and transglutaminase antibodies from serum became possible in the 1980s
and 1990s, respectively, the high prevalence and wide clinical presentation of celiac disease started to
become evident [5,10].
Gastrointestinal related symptoms and signs such as anemia, impaired growth, decreased bone
mineral density, and micronutrient deficiencies were recognized from early on to be associated with
untreated celiac disease. Although these were initially thought to be present only in connection with
malabsorption, it was later understood that they could also be a sole manifestation [11–13]. Dermatitis
herpetiformis was among the first extra-intestinal symptoms of celiac disease recognized [14].
Later, other organ systems were found to be affected, when, for example, patients with earlier
unexplained neurological and articular symptoms were diagnosed. In addition, as a result of the
increased screening, the symptoms common in the general population, such as headache and tiredness,
were often recognized in celiac disease patients. However, their true association to the disease and
especially the response to the dietary treatment remains controversial [15]. Altogether, it is important
to remember the unspecificity and complexity of the above-mentioned symptoms, as they may be
present also in many other common disorders, such as irritable bowel syndrome (IBS), chronic fatigue
syndrome, and migraine.
3. Variable Definitions for Symptoms and Findings
Clinical features of celiac disease are often classified categorically as ‘typical’ and ‘atypical’.
However, the definition for these terms is heterogeneous, which likely reflects the above-described
historical background. Extra-intestinal manifestations are particularly difficult to classify, even though
they may actually be even more common than the ‘typical’ symptoms. Consequently, a few years
ago, a group of experts encouraged the alternate terminology of ‘classical’ and ‘non-classical’ celiac
disease [16].
Another challenge in celiac disease is to discriminate the symptoms from the complications and
from the independently associated diseases. Celiac disease symptoms should be reversible with the
gluten free diet, whereas complications may be permanent and irreversible, especially if the initiation
of treatment is delayed (Figure 1). Well-known associated conditions with an increased risk for celiac
disease are for example type 1 diabetes, autoimmune thyroidal disease, and Down’s syndrome [17].
Whether the early diagnosis and treatment of celiac disease could prevent some of these conditions has
been debated [18,19]. Again, these conditions should not be confused with totally unrelated disorders
with often overlapping symptoms, such as IBS.
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Figure 1. Extra-intestinal manifestations and complications of celiac disease classified based on their
response to early initiated gluten-free diet (GFD) and typical age of development.
4. Epidemiology and Pathogenesis of Extraintestinal Manifestations
Although the existence of extraintestinal manifestations in celiac disease has been known for
decades, their prevalence remains poorly established. This issue is complicated by the variable
definitions and considerable age-related variations in the appearance of these symptoms (Table 1).
For example, poor growth and delayed puberty are evidently exclusively pediatric presentations,
whereas osteoporosis, infertility, and dermatitis herpetiformis are typical adulthood findings. Anemia,
liver abnormalities, and joint problems are seen in both pediatric and adult patients (Table 1). Although
celiac disease is known to be more common in females, the gender distribution of the extraintestinal
symptoms is currently mostly obscure [20].
The pathogenesis of most extraintestinal manifestations is also obscure. There is some
evidence that their presence is associated with an overall more severe clinical and histological
presentation [20], but neither the appearance nor severity seems to be just a direct consequence
of intestinal damage [21–26]. Another intriguing question is the balance between genetic and
environmental factors, as even identical twins with celiac disease may have completely different
phenotype [27]. The at least partially different pathogenic background of the variable presentations
of celiac disease is further supported by the peculiar appearance of serological markers in some of
these conditions [6,22,24]. The clinical features and plausible pathophysiological mechanisms of the
best-characterized extraintestinal manifestations are further discussed below.
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Table 1. Prevalence of the best-characterized extraintestinal manifestations of untreated celiac disease
in children and adults.
Children Adults
% % References
Poor growth 1 11–70 - [20,28,29]
Short stature 1 4–33 3 [15,30–33]
Anemia 12–40 23–48 [12,15,20,28,30,32–34]
Neurological symptoms 4–52 24 [15,20,28,29,31]
Enamel defects 0–15 1–83 [20,29,32,33,35,36]
Liver abnormalities 1–57 2–5 [8,15,32]
Joint manifestations 1–10 2–9 [15,20,29,30,32,33]
Dermatitis herpetiformis 2–3 10–20 [20,30,32,37]
Osteoporosis 0 4–23 [15,32]
Infertility - 5 [9,15]
1 Definitions of poor growth and short stature have varied between the studies.
4.1. Poor Growth
Poor growth is likely one of the most common extraintestinal manifestations in pediatric celiac
disease, although defining its true prevalence is complicated by its variable definitions (Table 1).
We recently observed that impaired growth might be particularly common in children with a
younger age at diagnosis and a more severe overall presentation of the disease [11]. For example,
the malabsorption of nutrients and abnormalities in growth hormone-insulin-like growth factor axis
and/or in thyroid function have been suggested as pathogenic mechanisms [26,38,39], but further
studies are needed to confirm these findings.
4.2. Anemia
Anemia is a common extraintestinal manifestation of untreated celiac disease in all age groups
(Table 1). Like poor growth, the presence of anemia seems to be associated with a more severe
disease presentation [12,34]. Its prevalence could be expected to decrease over time as a result
of an earlier diagnosis and the generally improved nutritional status of children. Regardless,
celiac disease is still increasingly found in subjects with unexplained anemia [5]. With regards to
pathogenesis, malabsorption/deficiencies of iron, vitamin B12, and folic acid may be implicated [40].
However, the etiology of anemia in celiac disease might be more complex, as it may be present in
autoantibody positive individuals even before the development of enteropathy [41].
4.3. Neurologic Manifestations
Approximately one-fifth of celiac disease patients suffer from neurological manifestations
(Table 1). The most common of these are gluten ataxia and peripheral neuropathy [42], which often
present without accompanying gastrointestinal symptoms [43]. The pathogenesis of neurological
manifestations is still somewhat obscure. In gluten ataxia, gluten-dependent transglutaminase 6 (TG6)
autoantibodies targeted against the cerebellar cells may play a role and might be useful in the
diagnostics of this condition [6,22]. However, TG6 antibodies have also been detected in children with
celiac disease without association to neurological symptoms [23]. It remains to be proven whether this
could predict the later adult onset of neurological symptoms.
4.4. Dental Enamel Defects
Disturbances in the amelogenesis of permanent teeth is a well-defined finding in celiac disease,
but there are considerable variations in its reported prevalence (Table 1). Enamel defects have been
particularly common in older studies together with severe infant celiac disease and lower general
health [36]. It is possible that this manifestation is disappearing as, for example, is rickets related
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to celiac disease. However, for an accurate diagnosis the dental enamel should be evaluated by an
expert dentist. Malnutrition, hypocalcemia, and immunologic disturbances have been suggested as
causative factors of enamel defects [35], and the severity seems to be associated with the duration of
gluten-exposure [44].
4.5. Liver Abnormalities
Prevalence of hypertransaminasemia has been reported in older studies up to 57%, while more
recent studies report only 9–14% (Table 1), possibly again reflecting earlier diagnosis and milder
presentation of celiac disease. Usually the hepatic injury is mild and easily reversible, but in rare
occasions, celiac disease may lead even to liver failure [45]. The severity of hypertransaminasemia
seems to be associated with the presence of malabsorption, high values of celiac autoantibodies,
and advanced duodenal lesion [8,46], and the suggested mechanisms include altered gut permeability
leading to an increased exposure to hepatotoxins in the portal circulation [47]. Interestingly,
TG2 autoantibody deposits have been found in liver biopsies from affected patients and could
contribute to the hepatocellular damage [21]. It is also important to keep in mind that celiac patients
have overrepresentation of coexisting liver diseases such as autoimmune hepatitis, primary biliary
cholangitis, and primary sclerosing cholangitis [48].
4.6. Joint Manifestations
Variable joint symptoms are quite often, although again inconsistently, reported in celiac disease
(Table 1). The observed symptoms are usually described vaguely as arthralgia rather than objective
synovitis [20,49]. However, subclinical synovial effusion and sacroiliitis have also been reported [50–52].
Differential diagnosis is challenging and includes, for example, growing pains in children and variable
musculoskeletal complaints and arthrosis in adults. Once again, it should be remembered that
celiac disease is associated with many autoimmune conditions, including rheumatologic diseases
such as Sjögren’s syndrome [53], juvenile rheumatoid/idiopathic arthritis [54], and systemic lupus
erythematosus [55]. At present, the pathogenesis of the joint symptoms in celiac disease remains
entirely speculative.
4.7. Dermatitis Herpetiformis
Dermatitis herpetiformis is a dermatological manifestation of celiac disease that usually appears
in adulthood (Table 1). The characteristic itching and blistering rash appears mostly on elbows, knees,
and buttocks. In contrast to intestinal celiac disease, dermatitis herpetiformis is more common in males
than females [7]. The diagnosis is based on skin biopsy showing characteristic IgA deposits in the
papillary dermis next to the lesion [56]. Interestingly, besides TG2, dermatitis herpetiformis patients
can also develop autoantibodies targeted against epidermal transglutaminase 3 [24]. Even though the
characteristic rash is the primary manifestation, up to 72% of the patients also have enteropathy [57].
Interestingly, the incidence of dermatitis herpetiformis seems to be decreasing in contrast to other
forms of celiac disease [7]. Furthermore, ‘classical’ celiac disease patients with poor dietary adherence
can change their phenotype to dermatitis herpetiformis over time [58].
4.8. Bone Disease
Rickets is a classical finding in children with celiac disease, but it is nowadays rarely seen in
developed countries. On the contrary, osteoporosis is common in adult celiac disease patients (Table 1),
particularly in elderly patients and in postmenopausal women. The malabsorption of calcium and
vitamin D may lead to secondary hyperparathyroidism and subsequently a high bone turnover and
osteoporosis [59]. Increasing the circulating cytokines and an altered balance of bone turnover have also
been suggested to play a role [60,61]. Neutralizing autoantibodies against osteoprotegerin have been
detected in celiac disease patients [25], but their true role in the development of osteoporosis remains
contradictory [62]. Decreased bone mineral density can also be seen in screen-detected patients [63],
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even before the development of enteropathy [64]. These observations emphasize the importance of
early diagnosis of celiac disease to prevent advanced bone disease and subsequent fractures.
4.9. Problems in Reproductive and Endocrine Systems
Delayed puberty can be observed in children with untreated celiac disease [15,32], and various
problems in reproductive health, such as infertility, recurrent miscarriages, and intrauterine growth
restriction, have been reported in adult female patients [9,15]. The pathogenesis of delayed puberty in
celiac disease is unknown, although it is a common finding also in many other chronic diseases during
adolescence. However, there are several hypotheses for the pathogenesis of reproductive system’s
maladies. Untreated celiac disease may lead to deficiencies of micronutrients such as zinc, selenium,
and folic acid which are important during pregnancy and fetal development, anemia may also have
a role [9]. Celiac disease may affect other hormonal systems, for example, TG2 autoantibodies are
able to bind to TG2 in thyroid tissue and the celiac autoantibody titers have been shown to correlate
with the antithyroperoxidase antibody titers [65]. However, this should not be confused with the
overrepresentation of celiac disease among children with autoimmune thyroid disease due to a shared
genetic background [66].
4.10. Other Extraintestinal Manifestations
Besides the above-mentioned, several other extraintestinal manifestations have been suggested
to be associated with celiac disease. Aphtous ulcers, headache, and fatigue are frequently reported
but unspecific clinical findings [15,31,35]. Several neuropsychiatric conditions including learning
disorders, developmental delay, and attention deficit hyperactivity disorder have also been associated
with celiac disease [31], as well as are psychiatric disorders including depression, anxiety, and even
schizophrenia [15,67]. In addition, there are reports about possible associations between celiac disease
and uveitis, eczema, psoriasis, asthma, and various cardiovascular symptoms [68–71]. However,
because of the common and non-specific nature of these conditions, a true pathogenic relationship to
celiac disease requires further evidence [15,72].
5. Effects of Dietary Treatment to the Extraintestinal Manifestations
In general, a gluten-free diet is an effective treatment for celiac disease. However, the dietary
response might be faster and more complete in children than in adults [73,74]. Extraintestinal
manifestations also have a good prognosis in children if appropriately treated with a gluten-free
diet (Table 2) [8,73,75], but in adults and in a subgroup of children, the dietary response might be
incomplete [12]. In such cases, the possibility of coexisting conditions should be remembered. Dapsone
medication is often needed as an additional therapy in dermatitis herpetiformis for some time [75].
A gluten-free diet has also been shown to be beneficial for more advanced extraintestinal
manifestations, such as a low bone mineral density, liver failure, and infertility [9,13,46,76–78], but here,
the timing of the diagnosis is crucial (Table 2). Early developing complications such as dental enamel
defects should actually be treated even before their appearance [44]. In children with poor growth,
a significant catch-up growth is usually achieved after the beginning of dietary treatment and thus
reduced adult height is uncommon [78,79]. However, growth problems should likely be treated at
latest in puberty, in order to avoid suboptimal height development [80–82]. With regards to bone
health, patients diagnosed in childhood seem to have no increased risk for osteoporotic fractures [83],
but again, in order to achieve optimal bone accrual, an early diagnosis is beneficial [84].
Nutrients 2018, 10, 1015 7 of 14
Table 2. Response of extraintestinal manifestations in celiac disease to a gluten-free diet (GFD).
Manifestation Response Comments References
Anemia Yes Sometimes slow or incomplete response [12,15]
Dermatitis herpetiformis Yes Dietary response may be slow andrequire additional Dapsone medication [15,75]
Transaminasemia Usually Often mild and reversible; in rare casesmay lead to liver failure [8,45]
Poor growth Variable May lead to reduced adulthood heightif not treated before puberty [15,82]
Neurological symptoms Variable In children, usually good response, butin adults, possibly irreversible [6,43]
Decreased bone mineral density Variable Initiation of GFD before school age maybe needed for optimal bone accrual [13,76,84]
Joint problems Variable Coexisting musculoskeletal diseaseshould be excluded if poor response [15]
Enamel defects Infrequently Early appearance and irreversible inpermanent teeth [44]
Infertility Unclear Conflicting results [9,77,85]
Non-adherence is the most common reason for an unsatisfactory treatment response [15,73].
Nevertheless, some extraintestinal manifestations may not improve entirely despite an apparently
strict diet, which may reflect their more complex etiology [15,72,73], but it is also possible that at least
a part of them are in fact related to disorders other than celiac disease. Accordingly, Jericho et al. found
that almost 30% of the children with a failure of catch-up growth on a gluten-free diet to have some
co-existing condition [15]. Therefore, additional reasons for poor response should be sought in cases
with proven adherence. True pediatric refractory celiac disease is almost non-existent and one should
be very cautious before making such a diagnosis [86].
6. Importance of Early Diagnosis
As discussed, it seems that most of the advanced extraintestinal manifestations might be
preventable by the early diagnosis of celiac disease. One way to increase the diagnostic yield would
be screening of at-risk groups. Counterweighting this approach is the burden of a gluten-free diet,
which is challenging to maintain, socially restrictive, and expensive. This may lead to reduced quality
of life particularly in patients with negligible symptoms. There is, however, some evidence that
even apparently asymptomatic adults may already have advanced histological disease and benefit
from the diet [63,87]. Furthermore, a long diagnostic delay may increase the risk of poor clinical
response [73,88,89]. This issue is less well defined in screen-detected children, but there is data showing
that they may also experience unrecognized symptoms, including extraintestinal manifestations [90,91],
and benefit from an early diagnosis [91–94].
An unsolved question is that a part of screened individuals may have a so-called potential celiac
disease with positive celiac autoantibodies but normal villi, and thus do not fulfil the current diagnostic
criteria [95]. This might be an early stage of developing celiac disease, but at present, more evidence
about the natural history of this condition is warranted [96].
Population-based mass screening would be a very effective approach to finding unrecognized
celiac patients, but is currently not recommended because of the lack of scientific evidence [95,97,98].
Major open questions concerning such a wide-scale screening are the above-mentioned challenges in
the diagnostics of patients with early or potential celiac disease, and the balance of the benefits and
harms of the treatment for asymptomatic patients. Furthermore, the cost-effectiveness of screening
is particularly important in these circumstances, but, unfortunately, this issue is currently very
scarcely studied.
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All in all, the current recommendations about screening for celiac disease have been varying
between countries and between children and adults [95,98,99]. However, most organizations
recommend a targeted at-risk group screening, this usually including first-degree relatives of celiac
disease patients and those suffering from type 1 diabetes [95,99]. Meanwhile, before further evidence
about screening is provided, active case finding is especially important. By carrying this out efficiently,
at least part a of the patients with extraintestinal manifestations could be diagnosed before appearance
of permanent complications.
7. Conclusions
In recent years, we have witnessed an upsurge of interest towards different gluten-related
conditions, demonstrated, for example, by the rapid increase of the popularity of self-adopted
gluten-free lifestyle. This notwithstanding, the clinical prevalence of officially diagnosed celiac disease,
is all but satisfactory. This is worrisome, as the condition is proven to be associated with an increased
risk of long-term complications that could very likely be prevented by timely diagnosis and initiation
of a gluten-free diet.
As wide-scale serological screening is currently not recommended, we should aim to improve
the physicians’ and other allied health professionals’ knowledge of the diverse presentations of celiac
disease. For pediatricians, this especially means the identification of the manifestations that can present
already at early childhood and may lead to permanent problems if undetected. Then again, many
extraintestinal symptoms may appear later in life and should thus be known by physicians of relevant
adult subspecialties. It is important to acknowledge the critical role of primary healthcare in these
circumstances, as only effective first-line case finding can lessen the ill-health caused by untreated
celiac disease at the population level. Therefore, we should educate particularly the primary care
providers, in order to understand the value of the early detection of this multifaceted condition.
In the future, we need more information on the prevalence, age of appearance, dietary response,
and long-term prognosis of the variable extraintestinal features of celiac disease. Moreover, at present,
the details of the pathogenesis and reasons for the substantial phenotype heterogeneity in celiac disease
remain mostly obscure. This information could, besides improving the diagnostics of celiac disease,
also provide novel insight of the development of autoimmune diseases in general.
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